Physician profile
Long Huynh-Duc
NPI 1447572169
$278,033.64
in general payments reported to CMS, 2019-2025
47 companies · $3,892 in 2025
The $3,892 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $36K · 2021: $43K · 2022: $31K · 2023: $14K · 2024: $6,310 · 2025: $3,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,412.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,856.25 |
| Education | $106.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81,484.98 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Amgen INC. | $63,988.42 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Celgene Corporation | $45,244.15 | 2019-2024 | Orencia |
| Mallinckrodt Enterprises LLC | $17,474.30 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13,103.40 | 2021-2025 | Saphnelo, Evusheld |
| Regeneron Healthcare Solutions, INC. | $11,528.07 | 2019-2020 | |
| Horizon Therapeutics Plc | $11,046.58 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $6,658.30 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $5,651.11 | 2019 | |
| Janssen Biotech, INC. | $4,513.39 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Mallinckrodt Hospital Products INC. | $2,964.90 | 2020-2025 | Acthar |
| Abbvie INC. | $2,449.41 | 2019-2025 | |
| Ucb, INC. | $1,730.88 | 2019-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $1,649.01 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,583.63 | 2019-2025 | Benlysta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,497.06 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,337.20 | 2019-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $856.83 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $790.24 | 2019-2025 | Cyltezo, Ofev |
| Genentech USA, INC. | $355.23 | 2019-2025 | Actemra, Rituxan |
| Aurinia Pharma U.S., INC. | $316.37 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $237.27 | 2020-2024 | Strensiq |
| Organon LLC | $216.80 | 2021-2025 | Hadlima |
| Actelion Pharmaceuticals US, INC. | $183.25 | 2021-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $150.57 | 2019-2025 | Spectra Wavewriter |
| Radius Health, INC. | $144.21 | 2019-2025 | Tymlos |
| Sobi, INC | $108.14 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $104.69 | 2023-2025 | Idacio |
| Pacira Therapeutics, INC. | $94.45 | 2019-2020 | |
| Bioventus LLC | $87.37 | 2021-2023 | Durolane |
| Kiniksa Pharmaceuticals International, Plc | $82.20 | 2024 | Arcalyst |
| Sandoz INC. | $69.15 | 2022-2024 | Hyrimoz |
| Tersera Therapeutics LLC | $63.20 | 2022 | |
| Abbott Laboratories | $50.46 | 2021-2025 | Octrode |
| Merck Sharp & Dohme LLC | $40.33 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $37.40 | 2024 | |
| Kyowa Kirin, INC. | $28.30 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $16.08 | 2023 | Zilretta |
| Antares Pharma, INC. | $15.69 | 2019 | |
| Invivyd INC | $15.47 | 2025 | Pemgarda |
| Mylan Institutional INC. | $15.12 | 2023 | Hulio |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2024 | Truxima |
| Kiniksa Pharmaceuticals, Ltd. | $12.83 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $11.70 | 2019 | |
| Medexus Pharma, INC. | $11.33 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Huynh-Duc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.